INR:9445. teen patti taas Gilead's AIDS drug Biktarvy shows high viral suppression in Phase III clinical trial The Yangtze River Delta Sub-center of the National ...

Merck's experimental two-drug combination met the main goal of significantly suppressing replication of the HIV-1 virus in ...

This article discusses the risk and opportunities of six major constituents of PJP ETF: Pfizer, Amgen, Gilead, AbbVie, BMY, ...

However, the combination of Merck's approved doravirine and investigational islatravir didn't prove superiority over Gilead's ...

Gilead Sciences, Inc. (NASDAQ:GILD), a biopharmaceutical company, discovers, develops and commercializes medicines to address ...

GILD has put up a steady performance in 2024, with a new drug approval, positive data readouts and strong quarterly results.

U.S. drugmaker Merck said on Thursday its experimental combination treatment for some adults with HIV-1 infection met the ...

This issue highlights a broader concern regarding medication coverage and affordable health care. It underscores the critical ...

The Maine Bureau of Insurance announced Monday that the carrier reversed its initial decision and will cover eight HIV ...

Investors are bullish on Gilead as the stock surges on successful launches and strong financial health, offering potential ...

For years, Gilead Sciences was dead money for shareholders. Shares of the drugmaker, with a market capitalization of just ...